CN1400016A - 清血降脂胶囊 - Google Patents
清血降脂胶囊 Download PDFInfo
- Publication number
- CN1400016A CN1400016A CN 02135419 CN02135419A CN1400016A CN 1400016 A CN1400016 A CN 1400016A CN 02135419 CN02135419 CN 02135419 CN 02135419 A CN02135419 A CN 02135419A CN 1400016 A CN1400016 A CN 1400016A
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- capsule
- radix
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 46
- 239000008280 blood Substances 0.000 title claims abstract description 46
- 239000002775 capsule Substances 0.000 title claims abstract description 28
- 238000004140 cleaning Methods 0.000 title claims description 24
- 239000003814 drug Substances 0.000 claims abstract description 30
- 241000190633 Cordyceps Species 0.000 claims abstract description 12
- 241000222336 Ganoderma Species 0.000 claims abstract description 12
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 12
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 12
- 235000008434 ginseng Nutrition 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 9
- 238000010298 pulverizing process Methods 0.000 claims abstract description 9
- 241000208340 Araliaceae Species 0.000 claims description 11
- 241000180649 Panax notoginseng Species 0.000 claims description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 11
- 241000195474 Sargassum Species 0.000 claims description 11
- 241000221377 Auricularia Species 0.000 claims description 10
- 241001489978 Eupolyphaga Species 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 241000233948 Typha Species 0.000 claims description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 8
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 241000748223 Alisma Species 0.000 abstract 1
- 244000028550 Auricularia auricula Species 0.000 abstract 1
- 235000000023 Auricularia auricula Nutrition 0.000 abstract 1
- 235000014493 Crataegus Nutrition 0.000 abstract 1
- 241001092040 Crataegus Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000009427 jiangzhi Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000008911 qingzhi Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了一种清血降脂胶囊,包括下列组分:人参:10~20份;灵芝:3~5份;冬虫夏草:5~10份;泽泻:5~10份;大黄9~15份;木耳:5~7份;山楂:7~10份;土鳖虫:7~10份;丹参:10~15份;三七:5~10份;蒲黄9~15份;海藻:5~7份;将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。通常上述胶囊还包括桃仁:5~10份;和/或虎杖:10~15份;和/或昆布5~7份;和/或红花:5~10份。该清血降脂胶囊在人体中起效快,短期内可明显降脂,疗程短,不会损害人体,为绿色保健药物。
Description
所属技术领域
本发明涉及一种药物,具体涉及一种中药,更具体地说涉及一种治疗高血脂的清血降脂胶囊。
背景技术
随着人们生活水平的提高,由于不良的饮食习惯和饮食结构以及生活方式,各种“富贵病”如糖尿病、心血管病、动脉粥样硬化、脂肪肝等的发病率、死亡率在持续增长,产生上述各种疾病的罪魁祸首为高血脂症,因此高血脂在现今社会作为导致动脉粥样硬化的独立危险因子,越来越受到医学界的重视。动脉粥样硬化的发生通常是由于动脉中血液粘度增高,血液流动缓慢,血液中过多的脂质沉积于血管壁,在动脉血管壁上形成粥样斑块造成。脑部动脉硬化可引起头晕、记忆力减退、甚至痴呆,也能引起脑血栓或脑溢血;心脏冠状动脉硬化可引起心慌、胸闷、气短,严重者可导致心肌梗塞;眼底毛细血管的阻塞可造成视力受损,甚至失明;肾脏毛细血管阻塞可导致肾功能衰竭。血脂长期升高,脂肪便会在肝脏堆积形成脂肪肝,最终导致肝硬化,所以预防和治疗高血脂病刻不容缓。预防高血脂并应当养成良好的饮食和生活习惯,而一旦患有高血脂病应当及时治疗。目前治疗高血脂病的药物大体分为中药和西药两种,中药现在市场上销售和使用的有“999降脂胶囊”、“汉林清脂胶囊”等,但现有的中药疗效不显著,起效慢,疗程时间长,药物对血清总胆固醇(TC)、血清甘油三脂(TC)、全血粘度的增高不能同时降低,并且价格昂贵,患者不宜接受。在西药方面降脂(调脂)药物通常有4~5种,近年疗效肯定、运用最多的有两类:一类为他汀类:常用辛伐他汀(舒降之)、普伐他汀及洛伐他汀等;另一类为:贝特类:常用非诺贝特、吉非罗齐等。他汀类抑制胆固醇合成,主要用于以总胆固醇升高为主及混合型高脂血症,即胆固醇与甘油三脂同时升高的病症;贝特类用于以甘油三脂升高为主型。他汀类明显降低血清密度、脂蛋白胆固醇浓度,同时轻中度降低甘油三脂以及轻度升高密度脂蛋白胆固醇水平。但西药用药时间太长,一般需要常年持续用药才能使血脂水平控制在较正常范围内,并且西药的化学成分对人体有副作用,长期服用会引起肝脏、肾脏功能及人体的损害。
发明内容
本发明克服了上述降脂药物采用中药时疗效不显著、起效慢、疗程时间长;采用西药需长期服用,西药化学成分易伤害肝脏和肾脏的缺点,提供了一种清血降脂胶囊,该胶囊在人体中起效快,短期内可明显降脂,疗程短,不会损害健康,为绿色保健药物。
本发明公开了一种清血降脂胶囊,包括下列组分:人参:10~20份;灵芝:3~5份;冬虫夏草:5~10份;泽泻:5~10份;大黄9~15份;木耳:5~7份;山楂:7~10份;土鳖虫:7~10份;丹参:10~15份;三七:5~10份;蒲黄9~15份;海藻:5~7份;将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
胶囊药物填料的的制备方法为共知技术,其包括于水中多次煮沸过滤;将提取液浓缩;干燥;粉碎过筛;装入胶囊即可得到清血降脂胶囊。
上述清血降脂胶囊各组分的优选组成为:人参:13~18份;灵芝:4~5份;冬虫夏草:5~8份;泽泻:6~9份;大黄10~13份;木耳:6~7份;山楂:7~9份;土鳖虫:7~8份;丹参:12~154份;三七:7~10份;蒲黄9~13份;海藻:5~7份。
人参、灵芝、冬虫夏草、麝香具有益气开窍、清热解毒、活血散淤、滋补虚损的功效;大黄、泽泻、山查楂、蒲黄、虎杖具有泻热破积、行气活血、散淤化痰的功效;丹参、三七、土鳖、桃仁、红花具有活血化淤、通经软坚、消炎止痛的功效;昆布、海藻、女贞子、木而具有软坚散热、清热消痰的功效,诸要合用可促使脂质代谢,抑制动脉粥样硬化及斑块的形成,促使肠道蠕动,加快胆固醇排泄,减少胆固醇的吸收,降低甘油三脂、降低血粘度等的作用。
通常上述清血降脂胶囊还包括下列份数的组分:具有活血化淤、通经软坚、消炎止痛功效的桃仁:5~10份;
或红花:5~10份;
或具有泻热破积、行气活血、散淤化痰功效的虎杖:10~15份。
或具有软坚散热、清热消痰功效的昆布:5~7份。
将上述一种或多种组分加入清血降脂胶囊,诸药合用后,清血降脂胶囊的效果更好,疗效更加明显。
本发明中清血降脂胶囊是针对高血脂发病率高、危害性大,应以预防为主的特点,研究出预防、治疗结合,重点在预防,有病防止病情进展的有效药物。该药物药效显著,疗程短,一般一个疗程20天,一般患者一个疗程即可恢复正常指标。本发明清血降脂胶囊采用纯中药制剂,因此不会损害身体,为绿色保健药品。
具体实施方式
具体实施方式1:
一种清血降脂胶囊,包括下列组分:人参:10克;灵芝:5克;冬虫夏草:9克;泽泻:9.5克;大黄10克;木耳:5~7克;山楂:7~10克;土鳖虫:7~10克;丹参:15克;三七:6克;蒲黄14克;海藻:5克;将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
具体实施方式2:
一种清血降脂胶囊,包括下列组分:人参:16克;灵芝:4克;冬虫夏草:8克;泽泻:7克;大黄12克;木耳:6克;山楂:8克;土鳖虫:7.5克;丹参:13克;三七:7克;蒲黄13克;海藻:6克;将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
具体实施方式3:
一种清血降脂胶囊,包括下列组分:人参:10克;灵芝:3克;冬虫夏草:6克;泽泻:6克;大黄9.5克;木耳:6克;山楂:8克;土鳖虫:7.5克;丹参:11克;三七:6克;蒲黄10克;海藻:6克;桃仁:6克;虎杖:12克,将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
具体实施方式4:
一种清血降脂胶囊,包括下列组分:人参:19克;灵芝:4克;冬虫夏草:9克;泽泻:9克;大黄10克;木耳:5克;山楂:10克;土鳖虫:6克;丹参:10克;三七:10克;蒲黄14克;海藻:6克;昆布7克,将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
具体实施方式5:
一种清血降脂胶囊,包括下列组分:人参:10克;灵芝:5克;冬虫夏草:10克;泽泻:8克;大黄12克;木耳:6克;山楂:8克;土鳖虫:8克;丹参:13克;三七:10克;蒲黄15克;海藻:7克;红花:10克,将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
具体实施方式6:
一种清血降脂胶囊,包括下列组分:人参:10克;灵芝:3克;冬虫夏草:6克;泽泻:6克;大黄9.5克;木耳:6克;山楂:8克;土鳖虫:7.5克;丹参:11克;三七:6克;蒲黄10克;海藻:6克;桃仁:6克;虎杖:12克;昆布7克;红花:10克,将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
Claims (6)
1、一种清血降脂胶囊,包括下列组分:人参:10~20份;灵芝:3~5份;冬虫夏草:5~10份;泽泻:5~10份;大黄9~15份;木耳:5~7份;山楂:7~10份;土鳖虫:7~10份;丹参:10~15份;三七:5~10份;蒲黄9~15份;海藻:5~7份;将上述药物按传统工艺炮制,经烘干、粉碎,提取有效成分及浓缩装入胶囊而成。
2、根据权利要求1所述的清血降脂胶囊,其特征是:所述各组分的优选份数为:人参:13~18份;灵芝:4~5份;冬虫夏草:5~8份;泽泻:6~9份;大黄10~13份;木耳:6~7份;山楂:7~9份;土鳖虫:7~8份;丹参:12~154份;三七:7~10份;蒲黄9~13份;海藻:5~7份。
3、根据权利要求1所述的清血降脂胶囊,其特征是:所述组分还包括:桃仁:5~10份。
4、根据权利要求1所述的清血降脂胶囊,其特征是:所述组分还包括:虎杖:10~15份。
5、根据权利要求1所述的清血降脂胶囊,其特征是:所述组分还包括:昆布5~7份。
6、根据权利要求1所述的清血降脂胶囊,其特征是:所述组分还包括:红花:5~10份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021354197A CN1150942C (zh) | 2002-08-13 | 2002-08-13 | 清血降脂胶囊 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021354197A CN1150942C (zh) | 2002-08-13 | 2002-08-13 | 清血降脂胶囊 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1400016A true CN1400016A (zh) | 2003-03-05 |
| CN1150942C CN1150942C (zh) | 2004-05-26 |
Family
ID=4748192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021354197A Expired - Fee Related CN1150942C (zh) | 2002-08-13 | 2002-08-13 | 清血降脂胶囊 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1150942C (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330345C (zh) * | 2005-05-17 | 2007-08-08 | 广西梧州制药(集团)股份有限公司 | 一种治疗高血脂症的中药组合物及其制备方法 |
| CN103566047A (zh) * | 2013-12-02 | 2014-02-12 | 杭州国草生物科技有限公司 | 一种降血脂的冬虫夏草组合物 |
| CN104189408A (zh) * | 2014-09-28 | 2014-12-10 | 李长娟 | 一种有效治疗高血脂的中药制剂 |
| CN105435130A (zh) * | 2016-01-12 | 2016-03-30 | 福建中医药大学附属康复医院 | 一种治疗痰瘀阻络型血浊病的外用中药组方 |
-
2002
- 2002-08-13 CN CNB021354197A patent/CN1150942C/zh not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1330345C (zh) * | 2005-05-17 | 2007-08-08 | 广西梧州制药(集团)股份有限公司 | 一种治疗高血脂症的中药组合物及其制备方法 |
| CN103566047A (zh) * | 2013-12-02 | 2014-02-12 | 杭州国草生物科技有限公司 | 一种降血脂的冬虫夏草组合物 |
| CN103566047B (zh) * | 2013-12-02 | 2016-09-21 | 杭州国草生物科技有限公司 | 一种降血脂的冬虫夏草组合物 |
| CN104189408A (zh) * | 2014-09-28 | 2014-12-10 | 李长娟 | 一种有效治疗高血脂的中药制剂 |
| CN105435130A (zh) * | 2016-01-12 | 2016-03-30 | 福建中医药大学附属康复医院 | 一种治疗痰瘀阻络型血浊病的外用中药组方 |
| CN105435130B (zh) * | 2016-01-12 | 2019-10-08 | 福建中医药大学附属康复医院 | 一种治疗痰瘀阻络型血浊病的外用中药组方 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1150942C (zh) | 2004-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101690764B (zh) | 治疗心脑血管病的中药及其制备方法 | |
| CN1224614A (zh) | 防治心脑血管系统疾病药物及其制备方法 | |
| CN1150942C (zh) | 清血降脂胶囊 | |
| CN110327427A (zh) | 一种治疗早、中期高血压病的中药组合物及制备方法 | |
| CN101085233A (zh) | 降血压、血脂、血糖的民间中草药 | |
| CN1283497A (zh) | 一种治疗脑血管病的口服液及制备工艺 | |
| CN1101199C (zh) | 一种治疗高脂血症的中药胶囊制剂 | |
| CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
| CN1244367C (zh) | 一种治疗癫痫病的中药口服液 | |
| CN1255149C (zh) | 一种药物组合物 | |
| CN103735879A (zh) | 一种治疗颈动脉粥样斑块的中药汤剂 | |
| CN103784626A (zh) | 一种中药治疗动脉硬化性疾病的药物及其制备方法 | |
| CN1322558A (zh) | 一种抗肝癌药 | |
| CN1319562C (zh) | 一种消炎杀菌的中药制剂及生产方法 | |
| CN1857607A (zh) | 治疗心脑血管疾病的中药制剂及其制备方法 | |
| CN1228308A (zh) | 降胆固醇护心制剂 | |
| CN1762440A (zh) | 一种防治心脑血管疾病的药物 | |
| CN101301384A (zh) | 一种治疗动脉硬化的中药组合物 | |
| CN120267783A (zh) | 一种应用于可防治中风、血管血栓、动脉硬化、冠心病或腰腿疼痛的通络化栓中药组合物 | |
| CN1265829C (zh) | 一种能预防、治疗心脑血管疾病的保健食品 | |
| CN1075091A (zh) | 脑血栓片的制备方法 | |
| CN1352979A (zh) | 益气活血的中药 | |
| CN110694014A (zh) | 一种预防和治疗血栓的组合物 | |
| CN1965924A (zh) | 一种降脂扩冠药物 | |
| CN105343358A (zh) | 一种治疗冠心病的中药胶囊 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |